Quarterly European Insights

and loans or credits. This includes actions to raise awareness, enhance the exchange of knowledge, experiences and practices as well as regular updates on scientific evidence. The outcomes of this exploratory study appear to imply that access to financial products for persons with a history of cancer is a topic of attention in most European Member States. Furthermore, most Member States and key stakeholders are positive with respect to a further exploration of EU level action that would support access to financial products for persons with a history of cancer in all Member States.

FINANCIAL SERVICES

ESG FUNDS PERFORM BETTER, COST LESS THAN OTHER FUNDS - ESMA

The European Securities and Markets Authority (ESMA), the EU’s securities markets regulator, has published a study looking at the potential reasons behind the relatively lower ongoing costs, and better performance, of environmental, social and governance (ESG) funds compared to other funds. ESMA recently determined that ESG equity undertakings for collective investment in transferable securities (UCITS), excluding exchange-traded funds, were cheaper and better performers in 2019 and 2020 compared to non-ESG peers. Understanding the cost and performance dynamics of ESG funds is of particular interest as it may bring insights for the overall fund industry on how to make funds more affordable and profitable for retail investors. The full study is available here.

EUROPEAN LONG-TERM INVESTMENT FUNDS: COUNCIL ADOPTS ITS POSITION

The European Council has adopted its position to improve the European long-term investment funds (ELTIFs) regulation to facilitate long-term investment in the real economy. The updated regulation will make these investment funds more attractive to asset managers and investors, and develop the number of such investment funds in Europe. ELTIFs are important funds to help finance the green and digital transitions, and they can help finance small and medium-sized enterprises (SMEs). They have an important role to play in the deepening of the Capital Markets Union (CMU). ELTIFs are the only type of funds dedicated to longterm investments which can be distributed on a cross-border basis to both professional and retail investors. However, since its adoption, only a limited number of ELTIFs have been launched, and only in four member states (France, Italy, Luxembourg and Spain), due to significant constraints in the distribution process and stringent rules on portfolio composition.

SECURITY

NEW LEGISLATION ADDS TO EUROPOL’S RESPONSIBILITIES

The Council and the European Parliament have agreed to strengthen Europol’s capacity to better support member states in combating new threats in the Union. The text introduces improvements in areas such as research and innovation, processing of large data sets and cooperation with private parties and third countries. Europol may also propose opening a national investigation into noncross-border crimes affecting a common interest covered by an EU policy. It will be up to the national authorities to decide whether or not to comply with this request. Europol will also support member states in the processing of data transmitted by third countries or international organisations and may propose that member states enter information alerts in the Schengen Information System (SIS).

umanamedical.com

Heart monitors do not have to be cumbersome.

Our flagship product, Umana T1, is a novel medical telemonitoring system that seamlessly combines non-invasive, ultra-thin hardware together with state-of-the-art software that accurately guarantees the reading, transmission and analysis of heart activity, together with other vital parameters.

A At Umana Medical, we develop medical technologies aimed at the monitoring of critical vital signs. Our products help medical professionals work more closely with their patients, including athletes, by providing sophisticated methods of monitoring, analysis and sharing long-term vital signs data in the fields of cardiology, diabetes, and telemedicine. These include patient’ s diagnostic ECG, Respiratory Rate, Blood Pressure, Physical Activity, Heart Rate Variability, Arrhythmias and other heart abnormalities. This technology generates automated notifications upon detection of irregular patterns, putting your life in safer hands.

AAt Umana we also conduct and publish research together with international Universities, medical institutions and top pharmaceutical companies, making us a pioneer in answering the growing demand for vital signs monitoring medical devices.